Today's Daily Dose brings you news about FDA approval of Merck's Keytruda for yet another indication; Neurocrine's disappointing phase II study of Ingrezza in Tourette syndrome; Spring Bank's results from phase 2a segment of its ACHIEVE trial and Syndax' public offering.
from RTT - Biotech http://ift.tt/2rOW4VW
via IFTTT
No comments:
Post a Comment